Rilvegostomig - Astrazeneca
Alternative Names: AZD-2936Latest Information Update: 25 Jun 2024
At a glance
- Originator AstraZeneca
- Developer AstraZeneca; Daiichi Sankyo Company; Presage Biosciences
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants; TIGIT protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Biliary cancer; Non-small cell lung cancer
- Phase II Adenocarcinoma; Liver cancer; Solid tumours
- Phase 0 Squamous cell cancer
Most Recent Events
- 21 Jun 2024 AstraZeneca plans phase-III DESTINY-BTC01 trial for Biliary cancer (Combination therapy, Unresectable/Inoperable, Late-stage disease, Metastatic disease, First-line therapy) in Austria, Belgium, Brazil, Canada, Germany, Japan, South Korea, Netherlands and Taiwan(IV) in June 2024 , (NCT06467357)
- 26 Apr 2024 Phase-0 clinical trials in Squamous cell cancer (Metastatic disease, Recurrent) in USA (Intratumoural) (NCT06366451)
- 19 Apr 2024 Presage Biosciences and AstraZeneca plans a phase 0 trial for Squamous cell carcinoma (Metastatic disease, Recurrent) in USA (Intratumoural, Injection) in April 2024 (NCT06366451)